WebFrontiers in Endocrinology (Jan 2024) . Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders WebDec 1, 2024 · Shenzhen Chipscreen Biosciences Co., Ltd. 2024-12-01 21:54 1318. Share: SHENZHEN, China, Dec. 1, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) …
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Yahoo …
WebDec 16, 2024 · Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) was founded in Shenzhen on 2001, specializing in the research and … WebUncover the latest insider trading activity for Shenzhen Chipscreen Biosciences Co., Ltd. (688321). Know which insiders are buying and selling along with top shareholders and … bar laureano
Chipscreen Biosciences Company Profile - Craft
WebMar 2, 2024 · HONG KONG, March 1, 2024 /PRNewswire/ --Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide announced that it entered into a collaboration agreement with Shenzhen … WebGet the latest Shenzhen Chipscreen Biosciences Co Ltd (688321) real-time quote, historical performance, charts, and other financial information to help you make more informed … WebShenzhen Chipscreen Biosciences Co., Ltd. is a China-based company principally engaged in the research and development of original innovative molecular entity drugs. The Company specializes in the research and development of original innovative drugs in the three major therapeutic areas of cancer, metabolic diseases and immune diseases. bar laura lugano